Oct 2026· Drug Design, Development and Therapy· Vol 20, pp. 1-25· 0 citations· 173 references
Medicine
TL;DR
Proteomics strategies are discussed, which enable the profiling of adverse drug reactions, the dissection of resistance mechanisms, and the advancement of precision oncology in antitumor drug development and precision oncology.
Abstract
Abstract Proteomics, the comprehensive study of protein expression, localization, and modifications, has evolved from a fundamental research tool into a key complementary layer to genomics in antitumor drug development and precision oncology. This review highlights its multi-dimensional applications, including differential, chemical, and post-translational modification proteomics, for drug-target discovery and mechanism-of-action elucidation. It further discusses proteomics strategies, such as mass spectrometry-based quantitative approaches, protein microarray and single-cell proteomics, which enable the profiling of adverse drug reactions, the dissection of resistance mechanisms, and the advancement of precision oncology. To date, the translational maturity of these applications is uneven: proteomic biomarkers have entered prospective trials and informed molecular tumor board recommendations in selected Clinical Laboratory Improvement Amendments (CLIA) certified settings, whereas de novo proteomics-derived drug targets remain largely at the preclinical stage. By bridging basic research and clinical practice, proteomics provides a scientific framework that facilitates drug development and informs clinical translation.
ABSTRACT Introduction Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide, with outcomes depending on the stages at diagnosis. Genomic and transcriptomic classifications are largely inferential because the genotype–phenotype relationship is non-linear and is influenced by post-translational r...
P. Ramachandran, C.-S.-Y. Chen, C. Lee et al.· Espert Review of Proteomics· 0 citations
Mass spectrometry (MS)-based proteomics has emerged as a versatile platform in modern drug discovery, enabling system-wide interrogation of protein abundance, posttranslational modifications (PTMs), turnover, structural stability, and interactions with small molecules in native biological contexts. In this review, we i...
Ka Yang, Wei-Ping Tang, Tao-Sheng Chen et al.· Annual Review of Pharmacolog...· 0 citations
Targeted anticancer drugs, including CDK4/6 inhibitors, PARP inhibitors and PI3K inhibitors, have considerably improved outcomes in cancer treatment. However, their clinical application is still challenged by significant interindividual pharmacokinetic variability. This may lead to differences in drug efficacy and toxi...
M. Sertić, L. Turković, Z. Mlinarić et al.· Zbornik radova· 0 citations
Cancer immunotherapy has revolutionized oncology by harnessing the immune system to recognize and eliminate malignant cells. Despite remarkable clinical successes, a substantial proportion of patients fail to respond or develop resistance, highlighting the urgent need for reliable biomarkers to guide patient selection,...
Adeel Ahmed, Faridul Haq· International Journal of Mol...· 0 citations
Artificial intelligence (AI) is changing the way we discover anticancer drugs. It tackles the problems of traditional methods, such as prolonged timelines for drug development, higher costs, and substantial inter-patient heterogeneity. This review explains how AI is applied throughout the cancer drug pipeline. This inc...
Faizan Ul Haque Nagrami, Pahchan Shukla, Ruchi Yadav et al.· Frontiers in Oncology· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.